Recovery of the normal p53 response after UV treatment in DNA repair-deficient fibroblasts by retroviral-mediated correction with the XPD gene

被引:19
作者
Dumaz, N [1 ]
Drougard, C [1 ]
Quilliet, X [1 ]
Mezzina, M [1 ]
Sarasin, A [1 ]
Daya-Grosjean, L [1 ]
机构
[1] CNRS, UPR 42, Genet Mol Lab, F-94801 Villejuif, France
关键词
D O I
10.1093/carcin/19.9.1701
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Among the major responses of human cells to DNA damage is accumulation of the p53 tumor suppressor protein, which plays a crucial role as a cell-cycle checkpoint. We have already shown that this response is different in cells from the UV-hypersensitive human syndromes xeroderma pigmentosum (XP) and trichothiodystrophy (TTD), which overlap with each other and arise from mutations in genes involved in nucleotide excision repair. In this paper we report that correction of the repair defect by retroviral-mediated transduction of the wild-type XPD gene in XP-D and TTD/XP-D untransformed primary fibroblasts leads to a normal p53 response in these cells, Thus, the complemented cells, like normal human fibroblasts, require higher UV doses (10 J/m(2)) for p53 induction than the parental repair-deficient XP-D or TTD/XP-D cells (both mapping at the XPD locus), which accumulate p53 protein at very low UV doses (2.5 and 5 J/m(2)), The p53 protein levels return to normal 24 h after irradiation when W-induced lesions have been efficiently repaired by the restored NER activity. These data confirm our earlier results that p53 accumulation following UV treatment is directly related to the presence of unrepaired cyclobutane dimers on the transcribed strand of active genes.
引用
收藏
页码:1701 / 1704
页数:4
相关论文
共 21 条
  • [1] FUNCTIONAL RETROVIRAL VECTOR FOR GENE-THERAPY OF XERODERMA-PIGMENTOSUM GROUP-D PATIENTS
    CARREAU, M
    QUILLIET, X
    EVENO, E
    SALVETTI, A
    DANOS, O
    HEARD, JM
    MEZZINA, M
    SARASIN, A
    [J]. HUMAN GENE THERAPY, 1995, 6 (10) : 1307 - 1315
  • [2] Dumaz N, 1997, MOL CARCINOGEN, V20, P340, DOI 10.1002/(SICI)1098-2744(199712)20:4<340::AID-MC3>3.0.CO
  • [3] 2-N
  • [4] EVENO E, 1995, CANCER RES, V55, P4325
  • [5] p53 in growth control and neoplasia
    Gottlieb, TM
    Oren, M
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 1996, 1287 (2-3): : 77 - 102
  • [6] INDUCTION OF APOPTOSIS IN HELA-CELLS BY TRANS-ACTIVATION-DEFICIENT P53
    HAUPT, Y
    ROWAN, S
    SHAULIAN, E
    VOUSDEN, KH
    OREN, M
    [J]. GENES & DEVELOPMENT, 1995, 9 (17) : 2170 - 2183
  • [7] TFIIH: A key component in multiple DNA transactions
    Hoeijmakers, JHJ
    Egly, JM
    Vermeulen, W
    [J]. CURRENT OPINION IN GENETICS & DEVELOPMENT, 1996, 6 (01) : 26 - 33
  • [8] The recognition of DNA damage
    Jackson, SP
    [J]. CURRENT OPINION IN GENETICS & DEVELOPMENT, 1996, 6 (01) : 19 - 25
  • [9] A MAMMALIAN-CELL CYCLE CHECKPOINT PATHWAY UTILIZING P53 AND GADD45 IS DEFECTIVE IN ATAXIA-TELANGIECTASIA
    KASTAN, MB
    ZHAN, QM
    ELDEIRY, WS
    CARRIER, F
    JACKS, T
    WALSH, WV
    PLUNKETT, BS
    VOGELSTEIN, B
    FORNACE, AJ
    [J]. CELL, 1992, 71 (04) : 587 - 597
  • [10] KHANNA KK, 1993, ONCOGENE, V8, P3307